Peptides, comprising 2-99 natural amino acids in living organisms, are organic compounds with a molecular weight of less than 10,000 Da. Peptides represent a distinct class of pharmaceutical compounds, molecularly poised between small molecules and proteins, yet biochemically and therapeutically distinct from both. As intrinsic signaling molecules for many physiological functions, peptides present an opportunity for therapeutic intervention that closely mimics natural pathways and play a central role in numerous physiological processes in the human body, including hormones, neurotransmitters, or in inflammatory responses. Peptides have been investigated across the therapeutic spectrum, reflecting the potential utility across a wide range of indications, particularly for chronic disorders such as metabolic, oncology and inflammatory musculoskeletal diseases.
The research, development, and manufacturing of peptides pose a unique set of challenges that span various stages of the pharmaceutical pipeline. One significant challenge lies in the inherent complexity of peptide structures, often characterized by intricate sequences and specific folding patterns critical to their biological activity. Achieving optimal synthesis efficiency while maintaining high purity levels represents a constant challenge, particularly with longer or modified peptide sequences. Additionally, scalability can be an issue, as translating laboratory-scale synthesis to large-scale production demands meticulous optimization to ensure reproducibility. Balancing cost-effectiveness with the need for sophisticated analytical techniques for quality control further compounds the challenges. Addressing these hurdles requires interdisciplinary collaboration, innovative technologies, and a deep understanding of peptide chemistry to navigate the intricacies associated with bringing peptide-based therapeutics from research concepts to successful commercial manufacturing.
We are a full-service peptide-focused CRDMO with vertically-integrated capabilities in the development and manufacturing of peptide drugs. We had accumulated deep experience consisting of thousands of records on peptide molecule synthesis and purification, covering nearly all fields of peptide synthesis and the latest peptide chemical synthesis and modification technologies. Our team is highly adept in several advanced synthesis methods for complex and long peptide chains, such as solid-phase synthesis, liquid-phase synthesis, hybrid solid-liquid-phase synthesis, and fragment condensation synthesis. We have also mastered the technologies of super-long peptide chain synthesis, cyclopeptide synthesis, difficult sequence peptide synthesis, diversified peptide modification and multiple disulfide bridge peptides. We have established several R&D technology platform including OmniPeptSynth™、PeptiConjuX™、PeptiNuclide LinkTech™、GreenSynth Innovations™、Impurity Screening™. By bolstering our efforts in R&D, we reinforce our capacity to innovate, ensuring that we remain at the forefront of the field and continue to deliver advanced solutions to meet the evolving needs of our customers and the industry as a whole.
